| Drug Name |
Enalapril maleate |
| Drug ID |
BADD_D00767 |
| Description |
Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling.[A18459] Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes vasoconstriction and renal reabsorption of sodium ions in the kidneys. Ultimately, enalaprilat works to reduce blood pressure and blood fluid volume.
Commonly marketed under the trade name Vasotec, enalapril was first approved by the FDA in 1985 for the management of hypertension, heart failure, and asymptomatic left ventricular dysfunction. It is also found in a combination product containing [hydrochlorothiazide] that is used for the management of hypertension. The active metabolite enalaprilat is also available in oral tablets and intravenous formulations for injection. |
| Indications and Usage |
Indicated for the management of essential or renovascular hypertension [L6586] as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect.[label]
Indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis.[label]
Indicated for the management of asymptomatic left ventricular dysfunction in patients with an ejection fraction of ≤ to 35 percent to decrease the rate of development of overt heart failure and the incidence of hospitalization for heart failure.[label] |
| Marketing Status |
approved; vet_approved |
| ATC Code |
C09AA02 |
| DrugBank ID |
DB00584
|
| KEGG ID |
D00621
|
| MeSH ID |
D004656
|
| PubChem ID |
5388961
|
| TTD Drug ID |
D00SEB
|
| NDC Product Code |
0904-5502; 43744-122; 0187-0142; 50090-0692; 51672-4038; 51672-4040; 55289-694; 61919-372; 61919-813; 70518-0045; 70518-1564; 70934-875; 0904-5610; 53296-0035; 16714-442; 43547-546; 0187-0143; 50090-3378; 50090-6490; 51672-4037; 60760-392; 62135-589; 62135-592; 68645-607; 68788-8320; 70518-3715; 71335-1427; 71335-9649; 51927-3336; 51655-006; 51655-058; 51655-207; 60429-184; 63187-397; 63187-977; 68071-2670; 68788-7967; 68788-8061; 68788-8385; 70518-0028; 70518-1664; 71205-074; 71205-075; 71335-1854; 71335-1910; 60429-185; 63629-1526; 68071-1793; 68645-455; 68788-8096; 70518-1190; 55111-008; 62991-2769; 71052-103; 0187-0141; 51655-110; 51655-341; 60760-688; 63629-1522; 68645-606; 68682-712; 70518-2445; 72789-318; 49452-2706; 16714-443; 16714-445; 43547-548; 50090-4560; 50090-5976; 60760-226; 68645-456; 71335-9604; 0904-5611; 0187-0140; 52652-4001; 53808-1108; 60429-186; 62135-590; 68645-605; 68788-8437; 70518-2621; 71335-0305; 71335-1141; 72189-151; 72189-282; 16714-444; 23155-704; 50090-6437; 51672-4245; 53002-2008; 60429-183; 60760-575; 61919-277; 68071-2618; 69452-237; 70518-3572; 0904-5609; 17404-0009; 38779-0514; 43547-545; 61919-690; 68645-457; 68788-7671; 71335-0055; 71335-0478; 71335-9698; 23155-773; 31722-020; 50090-0689; 50090-3275; 60760-587; 60760-777; 62135-591; 63629-1525; 68071-3408; 68682-710; 68682-711; 68682-713; 68788-8284; 72789-329; 51552-0944; 64220-143; 66174-0074; 23155-705; 23155-772; 43547-547; 45865-404 |
| UNII |
9O25354EPJ
|
| Synonyms |
Enalapril | MK-421 | MK 421 | MK421 | Renitec | Renitek | Enalapril Maleate | Maleate, Enalapril |
